NEW YORK (GenomeWeb News) – Asterand subsidiary BioSeek will collaborate on multiple oncology and inflammation-focused projects with the Japanese pharmaceutical company Eisai, Asterand said today.
Under the two-year agreement, the BioMap platform, which includes cell-based models designed to replicate interactions that are found in pharmacology and toxicology, will be used in research projects in both the US and Japan.
The BioMap platform provides a database of reference profiles that can be compared to patterns and changes caused by drugs in order to provide insight into properties of compounds, such as their on-and off-target effects, dose responses, and discrimination of closely related compounds.
Specific financial terms of the agreement were not released, but they include license fees and milestone payments, said Asterand.